Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …

Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused numerous deaths
worldwide and poses significant challenges. Researchers have recently studied a new …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …